Therapeutic guidelines for the treatment of bone metastasis: A report from the American college of radiology appropriateness criteria expert panel on radiation oncology

Journal of Palliative Medicine

Volumn 12, Issue 5, 2009, Pages 417-426

  Janjan, Nora ^a   Lutz, Stephen T ^b,l   Bedwinek, John M ^c   Hartsell, William F ^d   Ng, Andrea ^e   Pieters, Richard S ^f   Ratanatharathorn, Vaneerat ^g   Silberstein, Edward B ^h   Taub, Robert J ⁱ   Yasko, Alan W ^j   Rettenmaier, Andrew ^k  

^a UNIVERSITY OF TEXAS   (United States)

^b Blanchard Valley Regional Cancer Center   (United States)

^c Missouri Cancer Care   (United States)

^d Advocate Good Samaritan Hospital   (United States)

^e HARVARD UNIVERSITY   (United States)

^f UMASS MEMORIAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^h Society of Nuclear Medicine   (United States)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

^j American Academy of Orthopaedic Surgeons   (United States)

^k TEXAS A AND M UNIVERSITY   (United States)

^l AMERICAN COLLEGE OF RADIOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; RADIOPHARMACEUTICAL AGENT;

ANALGESIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; ONCOLOGY; PAIN; PANCOAST TUMOR; PATHOLOGIC FRACTURE; PRACTICE GUIDELINE; PRODUCTIVITY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; SPINAL CORD COMPRESSION; TOXICITY; TREATMENT PLANNING;

BONE NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; PALLIATIVE CARE; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; UNITED STATES;

EID: 66749141846     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.9633     Document Type: Article

References (44)

1. Plunkett TA, Smith P, Rubens RD: Risk of complications from bone metastases in breast cancer. Implications for management. Eur J Cancer 2000;36:476-482.
2. Sherry MM, Greco FA, Johnson DH, Hainsworth JD: Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer 198658:178-182.
3. Sherry MM, Greco FA, Johnson DH, Hainsworth JD: Meta-static breast cancer confined to the skeletal system. An indolent disease. Am J Med 1986;81:381-386.
4. Knudson G, Grinis G, Lopez-Majano V, Sansi P, Targonski P, Rubenstein M, Sharifi R, Guinan P: Bone scan as a stratification variable in advanced prostate cancer. Cancer 1991; 68:316-320.
5. Lai PP, Perez CA, Lockett MA: Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy. Int J Radiat Oncol Biol Phys 1992;24:423-430.
6. Yamashita K, Denno K, Ueda T, Komatsubara Y, Kotake T, Usami M, Maeda O, Nakano S, Hasegawa Y: Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 1993;71:1297-1302.
7. Janjan NA: Radiation for bone metastases: Conventional techniques and the role of systemic radiopharmaceuticals. Cancer 1997;80(8 Suppl):1628-1645.
8. Joranson DE, Ryan KM, Gilson AM, Dahl JL: Trends in medical use and abuse of opioid analgesics. JAMA 2000;283: 1710-1714.
9. Liu L, Meers K, Capurso A, Engebretson TO, Glicksman AS: The impact of radiation therapy on quality of life in patients with cancer. Cancer Pract 1998;6:237-242.
10. Ward SE, Berry PE, Misiewicz H: Concerns about analgesics among patients and family caregivers in a hospice setting. Res Nurs Health 1996;19:205-211.
11. Weissman DE: Doctors, opioids, and the law: The effect of controlled substances regulations on cancer pain management. Semin Oncol 1993;20(2 Suppl 1)53-58.
12. Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A: Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage 1998;16:171-178.
13. Lubitz JD, Riley GF: Trends in Medicare payments in the last year of life. N Engl J Med 1993;328:1092-1096.
14. Hartsell WF, Scott CB, Bruener DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M: Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005;97:798-804.
15. Blitzer PH: Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 1985;55:1468-1472.
16. Tong D, Gillick L, Hendrickson FR: The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-899.
17. Janjan NA: An emerging respect for palliative care in radiation oncology. J Palliat Med 1998;1:83-88.
18. Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, de Haes H, Martijn H, Oei B, Vonk E, van der Steen-Banasik E, Wiggenraad RG, Hoogenhout J, Warlam-Rodenhuis C, van Tienhoven G, Wanders R, Pomp J, van Reijn M, van Mierlo I, Rutten E: The effect of a single fraction compared to multiple fractions on painful bone metastass: A global analysis of the Dutch Metastasis Study. Radiother Oncol 1999;52:101-109.
19. Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with a multi-fraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 1999;52: 111-121.
20. Barak F, Werner A, Walach N, Horn Y: The palliative efficacy of a single high dose of radiation in treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1987;13:1233-1235.
21. Chow E, Lutz, Beyene J: A single fraction for all, or an argument for fractionation tailored to fit the needs of each individual patient with bone metastases? Int J Radiat Oncol Biol Phys 2003;55:565-567.
22. Cole DJ: A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol (R Coll Radiol) 1989;1: 59-62.
23. Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, Yarnold JR: A prospective randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 1992;23:74-78.
24. Jeremic B: Single fraction external beam radiation therapy in the treatment of localized metastatic bone pain. A review. J Pain Symptom Manage 2001;22:1048-1058.
25. Kal HB: Single fraction radiotherapy is as effective as multiple fractions for palliating painful bone metastases. Cancer Treat Rev 2003;29:345-347.
26. Koswig S, Budach V: [Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study]. Strahlenther Onkol 1999;175:500-508.
27. McQuay HJ, Collins SL, Carroll D, Moore RA: Radiotherapy for the palliation of bone metastases. Cochrane Database Syst Rev 2000; CD001793.
28. Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR: Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986;6:247-255.
29. Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD: Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - A systematic review of randomized trials. Clin Oncol (R Coll Radiol) 2003;15:345-352.
30. van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, Leer JW: Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: Cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003;95:222-229.
31. Wu JS, Wong R, Johnston M, Bezjak A, Whelan T: Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594-605.
32. Alberts AS, Smit BJ, Louw WK, van Rensburg AJ, van Beek A, Kritzinger V, Nel JS: Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997;43:175-179.
33. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP, Bruland OS: High-dose samarium-153 ethylene diamine tetramethylene phos-phonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20: 189-196.
34. Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ, Mason MD, Quilty PM, Reed NS, Russell JM, Yardley J: Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. Semin Oncol 1993;20(3 Suppl 2):32-33.
35. Franzius C, Schuck A, Bielack SS: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:1953-1954.
36. McEwan AJ, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT: A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur Urol 1994;26(Suppl 1):26-31.
37. Porter AT, McEwan AJ: Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomized controlled trial. Semin Oncol 1993;20(3 Suppl 2):38-43.
38. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, et al: Results of a randomized phase-Ill trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-813.
39. Robinson RG, Prerston DF, Schiefelbein M, Baxter KG: Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995;274:420-424.
40. Roger CL, Speiser BL, Ram PC, Shaw JA, Thomas TA: Efficacy and toxicity of intravenous strontium-89 for symptomatic osseous metastases. J Brachytherapy International 1998;14:133-142.
41. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574-1581.
42. Windsor PM: Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: A report of a single centre's 10-year experience. Clin Oncol (R Coll Radiol) 2001;13:219-227.
43. Macklis RM, Cornelli H, Lasher J: Brief courses of palliative radiotherapy for metastatic bone pain: A pilot cost-minimization comparison with narcotic analgesics. Am J Clin Oncol 1998;21:617-622.
44. National Health Care Expenditures 1960-2005. Centers for Medicare and Medicaid Services, Office of the Actuary: Data from the National Health Statistics Group, www.cms.hhs.gov/NationalHealthExpendData/02- NationalHealthAccountsHistorical.asp#TopOfPage (Last accessed March 11, 2009).